HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Division of Oncology Research Studies
1 - 10 of 51
16BT052; Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ depletion for patients with BMF
The purpose of this research study is to test a new method of cell processing for stem cell transplants with an unrelated donor or partially matched related donor for patients with BMF who do not have a well matched related donor.
17-SIBS Study
The purpose of this research study is to understand the impact of transplant on the quality of life of the entire family including sibling donors, other siblings and parents.
22LL011; Epcoritamab in B-cell Neoplasms
CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia).
A Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Subjects With Severe Sickle Cell Disease
The purpose of this research study is to learn more about the safety and effects of CTX001 (the “Study Product”) in patients ages 12 to 35 years who have been diagnosed with severe sickle cell disease.
AALL1131; A Phase 3 Randomized Trial for HR B-ALL with Dasatinib Arm in Ph-like TKI Sensitive Mutations
The study compares 2 different experimental chemotherapy combinations with the usual chemotherapy combination given during post-Induction therapy.
AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.
AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia
This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).
Abemaciclib For Solid Tumors
The purpose of this study is to determine the highest safe dose of abemaciclib in patients with relapsed or treatment refractory solid tumors given in combination with the chemotherapy drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide (Part B).
ALRN-6924 in Pediatric Cancer
Evaluate the side effects and benefits of ALRN-6924 in patients with relapsed or treatment refractory solid tumor or brain tumor, and to determine the best dose of ALRN-6924 for children and adolescents.
BA3011 for advanced solid tumors
This study involves taking a study drug called BA3011. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma.